EU Ozempic Shortage: What Weight Loss Drug Demand Means for Patients

What Is Causing the EU Ozempic Shortage in 2026

The EU Ozempic shortage in 2026 is being driven by a collision between soaring off-label demand for weight loss and manufacturing capacity that has still not caught up with patient need. According to the European Medicines Agency (EMA), as of 30 July 2026, GLP-1 medicines including semaglutide (Ozempic, Wegovy) remain on the official EU shortage list across 14 member states. That figure confirms what pharmacists across the bloc have reported for months: this is not a resolved crisis, but an ongoing structural supply gap.

EU Ozempic Shortage: What Weight Loss Drug Demand Means for Patients

The underlying driver has not changed since the EMA's Medicine Shortages Steering Group (MSSG) first flagged the problem: demand for GLP-1 receptor agonists, originally developed and licensed for type 2 diabetes, has expanded far beyond that population as word spread of their effectiveness for weight loss. Emer Cooke, the EMA's Executive Director, said in a June 2024 briefing that she did not expect the shortage to be resolved that year, citing surging demand alongside the difficulty of scaling up complex biologic manufacturing. Two years on, her caution has proven accurate; the shortfall has persisted into mid-2026 rather than closing.

Eurostat data published in July 2026 helps explain why demand shows no sign of easing: EU obesity rates now affect an estimated 1 in 6 adults across the bloc. With obesity increasingly treated as a chronic disease rather than a lifestyle issue, clinical and off-label demand for GLP-1 injections continues to climb well beyond what manufacturers can currently supply.

Who Is Most Affected by the GLP-1 Medicine Shortage

Type 2 diabetes patients who rely on semaglutide to manage blood glucose are the group facing the most direct clinical risk, because unlike weight loss users they typically have no equivalent alternative therapy readily available at short notice. Pharmacists in Germany, France, the Netherlands, Spain, Italy, Belgium, Sweden and Poland have all reported intermittent stock-outs of specific doses, forcing patients to switch pharmacies, delay refills, or in some cases ration doses.

The social impact of this shortage reaches well beyond clinical statistics. Older diabetic patients on fixed incomes, who often have the least flexibility to travel between pharmacies or pay out-of-pocket for private alternatives, are disproportionately affected when their regular pharmacy cannot fill a prescription. In lower-income households across member states with weaker pharmacy density, particularly in rural regions of Poland, Spain and parts of Italy, a single stock-out can mean weeks without access to a nearby alternative supplier. Healthcare providers, meanwhile, are spending additional unpaid time each week phoning around pharmacies and adjusting treatment plans, an administrative burden that adds strain to already stretched primary care systems.

For readers tracking related economic pressures on EU households, our finance coverage looks at how rising out-of-pocket healthcare costs are affecting family budgets across the bloc.

How EU Member States Are Responding to the Shortage

Several EU governments have introduced prescribing restrictions in 2026 designed to prioritise diabetic patients over off-label weight loss users, following the MSSG's recommendation that national authorities "control and optimise distribution" of GLP-1 medicines. France's approach is among the most detailed: since its 2026 pharmaceutical reform package took effect, physicians must document therapeutic justification for semaglutide prescriptions on the national e-prescribing platform, and any off-label request for obesity management now requires referral from a specialised obesity clinic.

France: mandatory e-prescribing documentation and specialist referral for off-label obesity use.
Germany, Belgium, Netherlands: pharmacy-level dispensing guidance directing limited stock toward patients with a diabetes diagnosis.
Spain, Italy, Sweden, Poland: continued inclusion on national and EU shortage registers, with local health authorities advising GPs to avoid new off-label initiations where diabetic demand is unmet.

These measures reflect a bloc-wide shift in regulatory posture: rather than waiting for supply to catch up, member states are now actively rationing access at the prescribing stage. It is a policy response that treats the shortage as a medium-term reality rather than a temporary disruption.

News Analysis: Manufacturer Expansion Will Not Ease Shortages Until Next Year

Manufacturers have acknowledged the shortfall and are investing heavily in additional capacity, but their own timelines confirm relief is not imminent. Novo Nordisk has committed an investment reported at more than €2 billion (DKK 16 billion) to expand its GLP-1 production facility in France, with construction under way and completion phased between 2026 and 2028, expected to create over 500 new jobs at the site. That timeline is the crux of the story for patients: even with construction actively progressing, expanded output from this and other European sites will not fully ease shortages until next year at the earliest.

What this means in practice is that the 14-member-state shortage listing confirmed by the EMA on 30 July 2026 is unlikely to shrink significantly before 2027. The gap between clinical demand, inflated further by off-label weight loss use, and pharmaceutical-grade biologic manufacturing capacity cannot be closed overnight; scaling sterile injectable production involves lengthy regulatory validation on top of physical construction. For patients and prescribers, that means current prescribing restrictions and pharmacy rationing are likely to remain the operational reality across most member states well into next year, not a short-term stopgap.

What EU Patients Should Do

Patients affected by the shortage have several concrete options rather than simply waiting out the disruption.

Diabetic patients should contact their prescribing doctor immediately if a pharmacy cannot fill an Ozempic prescription, rather than skipping doses; many GPs can switch patients temporarily to an alternative glucose-lowering therapy while supply stabilises.
Patients using GLP-1 medicines off-label for weight loss should expect stricter documentation requirements in 2026 and should discuss with their doctor whether continued access requires a specialist obesity-clinic referral under their national rules.
Anyone rationing doses without medical guidance should seek advice from a pharmacist or GP first, since altering an injection schedule without supervision can affect both efficacy and safety.
Check national shortage registers maintained by member state health authorities, which are updated more frequently than EU-wide listings and can indicate which pharmacies or regions still have stock.

Readers wanting a broader view of how EU health policy is evolving around chronic disease treatment can find further analysis in our health articles, and the homepage at Baba International tracks ongoing EU regulatory developments as they are confirmed.

Baba International Editorial Team

Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.

Frequently Asked Questions

Is Ozempic still in shortage across the EU in 2026?

Yes. The European Medicines Agency confirmed on 30 July 2026 that GLP-1 medicines, including Ozempic, remain on the official EU shortage list across 14 member states, meaning the disruption has continued rather than resolved.

Why is there a shortage if manufacturers are expanding production?

Manufacturers including Novo Nordisk are investing in new capacity, such as an expansion exceeding €2 billion at a French production site, but construction and regulatory validation for biologic manufacturing take years. Full relief is not expected until next year at the earliest.

Will diabetic patients be prioritised over weight loss users?

In several member states, yes. Following EMA guidance urging authorities to control and optimise distribution, countries including France have introduced documentation and referral requirements that make it harder to access GLP-1 medicines for off-label weight loss while diabetic demand remains unmet.

What should I do if my pharmacy cannot fill my prescription?

Contact your prescribing doctor immediately rather than skipping or rationing doses. Your doctor can advise on temporary alternative therapies or help you locate pharmacies with available stock through national shortage registers.

Conclusion

The EU Ozempic shortage is a structural, multi-year supply problem rather than a temporary blip, driven by obesity rates now affecting an estimated 1 in 6 adults across the bloc and manufacturing capacity that will not fully catch up until next year. Diabetic patients face the greatest clinical risk, member states are responding with tighter prescribing rules, and manufacturers' own expansion timelines confirm the shortage will persist through the rest of 2026. Patients should engage their doctor directly rather than self-manage disruptions, and should expect prescribing restrictions to remain in place across most member states well into 2027.